patients with KRAS G12C+ non small cell lung cancer and brain metastases research hub

STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases

This study looks at a new drug, JDQ443, for people with a specific type of lung cancer (KRAS G12C+ non-small cell lung cancer) that has spread to the brain. Researchers want to see how well the drug shrinks brain tumours and controls the cancer's growth.